AUPH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Aurinia Pharmaceuticals Inc. (AUPH) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown strong financial performance in the latest quarter, the technical indicators are neutral to bearish, and analysts have downgraded the stock with concerns about its competitive positioning. Additionally, there are no significant positive catalysts or trading signals to suggest immediate upside potential.
The MACD is below zero and negatively expanding, indicating bearish momentum. RSI is neutral at 35.167, and moving averages are converging, showing no clear trend. The stock is trading near its support level of 14.277, with resistance at 15.247. Overall, the technical outlook is neutral to slightly bearish.
Strong financial performance in Q3 2025, with revenue up 8.41% YoY, net income up 119.87% YoY, and EPS up 130.00% YoY.
Analyst downgrade by Leerink to Market Perform, citing concerns over the competitive landscape and uncertainty around the long-term potential of its key product Lupkynis. No recent news or significant insider/hedge fund activity. Gross margin dropped by 2.45% YoY.
In Q3 2025, Aurinia Pharmaceuticals reported revenue of $73.47M, up 8.41% YoY. Net income increased significantly to $31.55M, up 119.87% YoY, and EPS rose to 0.23, up 130.00% YoY. However, gross margin declined to 88.87%, down 2.45% YoY.
Leerink downgraded the stock to Market Perform from Outperform with a price target of $16. Concerns were raised about the competitive landscape and the long-term potential of its key product, Lupkynis.
